In a forthcoming paper, the Review on Antimicrobial Resistance estimates that bringing new antimicrobials to market and improving their administration will cost about $25 billion – a significant sum, but one that pales in comparison to the costs to society if the problem is not checked. It is also roughly what two of the world’s largest pharmaceutical companies will spend this year buying back their own shares.